A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a).

Trial Profile

A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2015

At a glance

  • Drugs Deleobuvir (Primary) ; Faldaprevir (Primary) ; Ravidasvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Presidio Pharmaceuticals
  • Most Recent Events

    • 21 Jan 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Oct 2014 According to the ClinicalTrials.gov reocrd, planned end date changed 1 Sep 2014 to 1 Oct 2014.
    • 29 Aug 2014 According to the ClinicalTrials.gov reocrd, planned end date changed from 1 Aug 2014 to 1 Sep 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top